Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline

DUBLIN, Feb. 16, 2018 /PRNewswire/ --

The "Chronic Myeloid Leukemia (CML)" report has been added to ResearchAndMarkets.com's offering.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML.

Market Snapshot

• The CML market will experience a short period of growth followed by a decline in sales due to the onset of generic competition.
• The largest unmet needs in CML are overcoming TKI resistance and addressing patients with accelerated or blast phase disease.
• The number of incident chronic myeloid leukemia cases is expected to increase by 25% over the next 20 years.
• Generic imatinib will dominate first-line treatment as Sprycel and Tasigna compete for market share in the second line.
• Asciminib is currently the primary candidate in the pipeline, and may benefit patients progressing on available TKIs.

Key Topics Covered:

Forecast: Chronic Myeloid Leukemia

• Executive Summary
• Market Overview And Trends
• Market Definition And Methodology
• Asciminib
• Bosulif (Bosutinib)
• Gleevec (Imatinib)
• Iclusig (Ponatinib)
• Sprycel (Dasatinib)
• Synribo (Omacetaxine Mepesuccinate)
• Tasigna (Nilotinib)
• Primary Research Methodology

Treatment: Chronic Myeloid Leukemia

• Executive Summary
• Primary Research Methodology
• Disease Definition And Diagnosis
• Patient Segmentation
• Current Treatment Options
• Prescribing Trends

Epidemiology: Chronic Myeloid Leukemia In The Us, Japan, And 5EU

• Executive Summary
• Disease Background
• Sources And Methodology
• Forecast
• Epidemiologist Insight
• Strengths And Limitations
• Bibliography
• Appendix: Additional Sources

Marketed Drugs: Chronic Myeloid Leukemia

• Executive Summary
• Product Overview
• Product Profile: Bosulif
• Product Profile: Gleevec
• Product Profile: Iclusig
• Product Profile: Sprycel
• Product Profile: Synribo
• Product Profile: Tasigna

Pipeline: Chronic Myeloid Leukemia

• Executive Summary
• Clinical Pipeline Overview
• Comparator Therapy
• Product Profile (Late Stage): Asciminib

For more information about this report visit https://www.researchandmarkets.com/research/k7kr9g/global_chronic?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716